drugset / Trial / NCT00788424

Topical Application of AS101 for the Treatment of Psoriasis

NCT00788424

Phase 2 Withdrawn BioMAS Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

This protocol relates to a phase II randomized double blind, placebo controlled study of the AS101 topical application for the treatment of mild to moderate Psoriasis.

Timeline

Start
2008-11
Primary completion
2010-02
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Subject TRICHLOROTELLURATE Small molecule 4 % Topical

Indications